Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | May 24, 2012

Insights on Electrophysiology from Heart Rhythm 2012

 

Most advances in medicine are small and incremental, but once in a while there is a rapid leap forward that draws excitement and  provides a breath of spring air in an otherwise stagnant environment. This was the feeling at the Heart Rhythm Society (HRS) 2012 scientific sessions in Boston last week in response to two new technologies that may change the way electrophysiology is practiced. The first is Cameron Health’s subcutaneous implantable cardioverter defibrillator (S-ICD) pending final U.S. Food and Drug Administration (FDA) review. The second is a new technique called FIRM, used to clearly visualize electrical activity around rotor cores in atrial fibrillation patients to precisely guide ablations. In some cases, FIRM shortened the usual four- to six-hour ablation procedure time to just minutes.

Device-wise, the S-ICD system was a favorite and the Cameron booth was packed during much of the show. The system uses leads that are placed just under the skin under direct visualization, so there is no need for angiography and it eliminates the need for venous access, endovenous leads and cardiac lead fixation. The system was also designed to be extremely simple to use and program. Boston Scientific is working on a deal to purchase the company. If approved by the FDA later this summer, the S-ICD will be the first implantable EP device to use a subcutaneous lead system, likely the first of many devices to come. Click here to see a video or click here to read more about European trial results.

Procedurally, the FIRM technology discussed in a new EP technology session was a big topic of discussion. It offers a new way to visualize electrical activity in atrial fibrillation to more effectively and quickly ablate and terminate the arrhythmia. For more information, click here to read the story.

Perhaps because of growing interest in expanding or creating new EP programs, the HRS exhibit floor was noticeably packed with attendees, more so than other cardiology shows I’ve attended over the past couple of years.

A new study on the high malfunction rate of the Riata lead was presented at HRS, adding further concern about the lead. To watch the press conference video, click here.

I also created a video touching on some of the top trends and new technology highlighted on the expo floor of HRS. To watch the video, click here.

Finally, as healthcare marches toward total integration of all reports, imaging and waveforms into the electronic medical report, there has been increased interest in electrophysiology reporting modules. DAIC spoke to EP and IT expert Michael Mirro, M.D., who explained what hospitals should look for in these systems. To watch the video of this interview, click here.

 

Related Content

The Stereotaxis Genesis EP robotic navigation system.

The new generation Stereotaxis Genesis EP robotic navigation system.

News | EP Lab | September 01, 2021
September 1, 2021 — Stereotaxis and Shanghai Microport EP Medtech Co., Ltd.
Ventricular Tachycardia Recurrence, Hospitalization and Death Reduced With Catheter Ablation as First Line Therapy. Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and sudden cardiac death (SCD) death when catheter ablation is used as an early first-line treatment for patients with structural heart disease. Led by study coordinating center, the University of Chicago, The PAUSE-SCD trial. #HRS21
News | EP Lab | August 09, 2021
August 9, 2021 – Results from an international clinical trial show a significant reduction in risk of ventricular tac
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | August 09, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy.

An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy. 

News | EP Lab | August 05, 2021 | By Dave Fornell, Editor
August 5, 2021 —  A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and
EP lab ablation catheter. #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm contr
emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative...
Oral Contraceptives Cause Increased Risk of Cardiac Events in Woman With Long QT Syndrome. #HRS21 #HRS2021 #womenshealth
News | EP Lab | August 03, 2021
August 3, 2021 – Results from a new clinical trial show an increased risk of cardiac events, like sudden cardiac deat
A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021, the annual meeting of the Heart Rhythm Society (HRS). #HRS21 #HRS2021

A novel sinus node ablation technique provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021.

News | EP Lab | August 03, 2021
August 3, 2021 – A recent study unveiled a novel sinus node...
The Philips EPD Kodex system for the EP lab.
News | EP Lab | August 03, 2021
August 3, 2021 – A new analysis of the Catheter Ablation vs.
The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures.

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell

News | EP Lab | August 03, 2021
August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnso